Table 4.

Gene expression analysis using NanoString

Differences in gene expression in relapse patients compared with non-relapse patients at the time of TKI discontinuation
Gene	Log2 FC	Linear FC	p-value	BH p-value
BAGE	−1.430	−2.688	0.007	0.088
LTF	−1.050	−2.075	0.021	0.157
CEACAM8	−0.937	−1.916	0.033	0.193
SIGLEC1	−0.826	−1.773	0.043	0.227
ARG2	−0.813	−1.757	0.003	0.063
IRF5	−0.751	−1.684	0.000	0.002
CAMP	−0.724	−1.650	0.049	0.241
PLAUR	−0.719	−1.647	0.006	0.085
POU2AF1	−0.705	−1.631	0.002	0.053
IL21R	−0.685	−1.608	0.000	0.011
LCN2	−0.664	−1.585	0.039	0.214
IL11RA	−0.658	−1.577	0.000	0.018
CD33	−0.610	−1.527	0.000	0.011
CCR7	−0.603	−1.520	0.003	0.055
PTGS2	0.600	1.520	0.046	0.237
FCGR1A	0.647	1.570	0.025	0.170
CXCL10	0.758	1.690	0.020	0.154
CD160	0.779	1.720	0.002	0.053
IFNG	1.000	2.010	0.000	0.011
Differences in gene expression at the time of relapse compared with when TKI was discontinued in relapse patients
ENTPD1	−0.735	−1.664	0.000	0.019
FCGR1A	−0.673	−1.595	0.015	0.151
CD79A	0.606	1.520	0.002	0.077
CXCL5	0.799	1.740	0.001	0.044
CEACAM6	0.802	1.740	0.034	0.221

Abbreviations: TKI, tyrosine kinase inhibitor; FC, fold-change